lerapolturev + pembrolizumab

**lerapolturev + pembrolizumab** is a combination regimen under clinical investigation for cancer immunotherapy, specifically for recurrent glioblastoma. Lerapolturev (also known as PVSRIPO) is a recombinant, non-pathogenic poliovirus engineered to target malignant cells. It is designed to infect and destroy tumor cells and stimulate a robust immune response against the tumor. Pembrolizumab is a humanized monoclonal antibody that inhibits programmed cell death protein 1 (PD-1), effectively releasing the immune system's brakes and enhancing anti-tumor immunity. In the LUMINOS-101 phase 2 trial, lerapolturev is administered intratumorally, followed by intravenous pembrolizumab every three weeks. The regimen is well tolerated and being studied for its efficacy and safety in patients with recurrent glioblastoma[1][3][7].

Other names

lerapolturevpembrolizumabPVSRIPO